Introduction: Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical practice, in the treatment of several immune-mediated disorders, such as inflammatory bowel diseases, rheumatoid arthritis and more recently in psoriasis.
Case Report: A 35-year-old woman, suffering from Crohn's disease, diagnosed in 1994, successfully treated with infliximab at the dosage of 5 mg/Kg every 8 weeks, since 10 months ago, was referred to our Dermatology Department due to the development of erythematic-scaling confluent plaques on the scalp, back and umbilical fold. The skin biopsy confirmed the clinical diagnosis of psoriasis. Given the severity of the skin lesions and its relation with the anti-TNF-α, we decided to discontinue infliximab.
Discussion: Psoriasis results from the combination of polygenic predisposition and several triggering factors. Paradoxically, it has been described an increase of psoriasis induced by biologic agents. The pathogenic mechanism of such paradoxical effect has not yet been clearly elucidated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.
Sci Adv
January 2025
Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Aurora, CO, USA.
Programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) interactions are targets for immunotherapies aimed to reinvigorate T cell function. Recently, it was documented that PD-L1 regulates dendritic cell (DC) migration through intracellular signaling events. In this study, we find that both preclinical murine and clinically available human PD-L1 antibodies limit DC migration.
View Article and Find Full Text PDFHepatic ischemia-reperfusion (I/R) injury frequently occurs during the perioperative phase of liver surgery. Inappropriate activation of STING signaling can trigger excessive inflammation response to aggravate hepatic I/R injury. Dimethyl fumarate (DMF) is an FDA-approved immunomodulatory drug used to treat multiple sclerosis and psoriasis due to its notable anti-inflammation properties.
View Article and Find Full Text PDFTanshinone I Ameliorates Psoriasis-Like Dermatitis by Suppressing Inflammation and Regulating Keratinocyte Differentiation.
Drug Des Devel Ther
January 2025
Department of Dermatology, Second Xiangya Hospital, Hunan Key Laboratory of Medical Epigenomics, Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Central South University, Changsha, Hunan, People's Republic of China.
Background: Psoriasis is an immune-related inflammatory systemic condition characterized by dysregulated keratinocyte proliferation and chronic inflammation. Tanshinone I (Tan-I) has recently been discovered to have immunomodulatory properties, but its role and mechanisms in treating psoriasis remain unclear.
Objective: To evaluate the efficacy of Tan-I in the treatment of psoriasis and to determine the mechanisms involved.
An in-situ forming controlled release soft hydrogel-based C5a peptidase drug delivery system to treat psoriasis.
Int J Pharm
January 2025
Department of Chemical Sciences, Bernal Institute, University of Limerick, Ireland; SSPC Science Foundation Ireland Research Centre for Pharmaceuticals, University of Limerick, Ireland. Electronic address:
The potent pro-inflammatory cytokine, interferon gamma (IFN-γ), is an enticing therapeutic target because of its accelerator role in several acute and chronic inflammatory processes. In this work, poloxamer 407 is developed as an in-situ gelling polymer for a long-acting formulation to deliver a serine protease, C5a peptidase (ScpA) from Streptococcus pyogenes. ScpA is well known for its activity against the complement factor C5a but has also recently been shown to cleave IFN-γ in vitro into inactive fragments.
View Article and Find Full Text PDFInvestigation of the participation of the TRPV1 receptor in the irritant effect of dithranol in mice.
Eur J Pharmacol
January 2025
Graduate Program in Pharmacology, Federal University of Santa Catarina (UFSC), 88037-000 - Florianópolis (SC), Brazil. Electronic address:
Dithranol is one of the most effective topical medications for treating plaque psoriasis. However, its clinical use is limited by irritative adverse reactions to the skin, such as oedema, erythema, and pruritus, caused by poorly understood mechanisms. Because TRPV1 activation mediates skin irritation caused by several drugs, we conducted blind and randomised experiments in male and female C57BL/6 mice to elucidate the role of TRPV1 in dithranol-induced irritation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!